Tilray Brands (TLRY) is a diverse company operating in cannabis, craft beverages, hemp-based wellness, and entertainment across 20 countries. TLRY stock saw a 70% surge due to Trump’s mention of marijuana reclassification, alongside deepening European collaborations. The company’s fiscal fourth-quarter 2025 earnings showed revenue decline and widened losses, but international cannabis business grew. TLRY anticipates adjusted EBITDA growth for fiscal 2026, banking on Project 420 for operational efficiency. Analysts project losses in Q1 fiscal 2026 but foresee improvement by fiscal 2027. A potential reclassification of marijuana to Schedule III could reshape Tilray’s future and industry dynamics.

Read more at Yahoo Finance: Is Tilray Stock a Buy, Sell, or Hold for August 2025?